LAVA Therapeutics
Yahoo Finance • 12 hours ago
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the fourth quarter of 2025.... Full story
Yahoo Finance • 2 months ago
LAVA Therapeutics GAAP EPS of -$0.32 misses by $0.06
* LAVA Therapeutics press release [https://seekingalpha.com/pr/20200312-lava-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:LVTX [https://seekingalpha.com/symbol/LVTX]): Q2 GAAP EPS of -$0.32 misses... Full story
Yahoo Finance • 2 months ago
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
XOMA Royalty Corporation Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recent... Full story
Yahoo Finance • 2 months ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
BALA CYNWYD, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story
Yahoo Finance • 2 months ago
XOMA Royalty to acquire cancer drug developer LAVA Therapeutics
[Wooden blocks with text M and A on light blue paper, business concept. MA - short for mergers and acquisitions] Biotech royalty aggregator XOMA Royalty (NASDAQ:XOMA [https://seekingalpha.com/symbol/XOMA]) has agreed to acquire cancer dru... Full story
Yahoo Finance • 2 months ago
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) announced today they have ent... Full story
Yahoo Finance • 2 years ago
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and tolerability utilizing the Gammabody® platfo... Full story
Yahoo Finance • 2 years ago
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engage... Full story
Yahoo Finance • 2 years ago
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8 Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by SeagenPortfoli... Full story
Yahoo Finance • 2 years ago
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVATherapeuticsN.V. (Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engag... Full story
Yahoo Finance • 2 years ago
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
• LAVA-1207 for the treatment of prostate cancer will continue as the lead program • LAVA-051 Phase 1/2a clinical trial will be discontinued • Associated cost savings and initiatives are expected to extend the cash runway further into 2026... Full story
Yahoo Finance • 2 years ago
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory chronic lymphocytic leukemia and multip... Full story
Yahoo Finance • 3 years ago
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-d... Full story
Yahoo Finance • 3 years ago
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
Favorable safety profile to date, with no occurrence of high-grade (>2) cytokine release syndrome or dose-limiting toxicitiesPreliminary signs of anti-tumor activity were observed, with iRECIST stable disease (iSD) in 8 out of 14 evaluable... Full story
Yahoo Finance • 3 years ago
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
UTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-de... Full story
Yahoo Finance • 3 years ago
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engag... Full story
Yahoo Finance • 3 years ago
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engager... Full story
Yahoo Finance • 3 years ago
LAVA Therapeutics Announces Appointment of New Directors to the Board
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma de... Full story
Yahoo Finance • 3 years ago
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-d... Full story
Yahoo Finance • 3 years ago
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
UTRECHT, The Netherlands and PHILADELPHIA, Pa., Dec. 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gam... Full story
